DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



RA Denosumab on Bone Microstructure Study

Information source: Chinese University of Hong Kong
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: Denosumab (Drug); Alendronate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Chinese University of Hong Kong

Official(s) and/or principal investigator(s):
Lai-Shan Tam, MD, Principal Investigator, Affiliation: Chinese University of Hong Kong

Summary

The aim of this study is to compare the effects of denosumab and a current standard treatment on cortical and trabecular microarchitecture at the radius and second metacarpal in rheumatoid arthritis (RA) patients with low bone mineral density using high resolution peripheral quantitative computed tomography (HR-pQCT) during a 6-month open-label randomized controlled study. Forty ambulatory Chinese females, who consent to receive alendronate as standard treatment subjective to the randomization, will be enrolled in this study. Subjects will be randomized to 2 arms receiving: 1) subcutaneous injection of denosumab 60mg (Prolia«) every 6 months (n=20), or 2) oral alendronate weekly (Fosamax┬« once weekly 70 mg, n=20). In addition, all patients will be given a daily calcium supplement (1500mg caltrate /day) and 1 multivitamin tablet per day. Efficacy and safety assessment will be performed at baseline, month 3 and month 6. aBMD of lumbar spine, total hip and non-dominant distal radius will be measured using dual-energy X-ray absorptiometry (DXA) and microarchitecture of bone is measured at the non-dominant distal radius and the second metacarpal bone of the non-dominant hand using HR-pQCT.

Clinical Details

Official title: Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Changes from baseline in bone volumetric density at distal radius at 6th month

Secondary outcome:

Changes from baseline in trabecular bone microarchitecture at distal radius at 6th month

Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 6th month

Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 6th month

Changes from baseline in areal bone density at total hip at 6th month

Changes from baseline in areal bone density at lumbar spine at 6th month

Changes in areal bone density at distal radius at 6th month

Changes from baseline in bone volumetric density at distal radius at 3rd month

Changes from baseline in trabecular bone microarchitecture at distal radius at 3rd month

Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 3rd month

Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 3rd month

Changes from baseline in areal bone density at total hip at 3rd month

Changes from baseline in areal bone density at lumbar spine at 3rd month

Changes in areal bone density at distal radius at 3rd month

Detailed description: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease most typical in women. Generalized osteoporosis is common in RA, at axial and appendicular skeleton and in females and males. Denosumab is a fully humanized IgG monoclonal antibody that targets the receptor activator of nuclear factor κB ligand (RANKL). Denosumab prevents the binding and activation of the RANK receptors on the osteoclasts and hence inhibits osteoclasts formation, activation, function and survival. Denosumab results in more rapid and greater reductions in bone remodeling and correspondingly greater increases in areal bone mineral density (aBMD) at all skeletal sites. Denosumab was approved by FDA in June 2010 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. Denosumab (Prolia®) is also licensed in Hong Kong. A high-resolution peripheral quantitative computed tomography (HR-pQCT) capable of achieving an isotropic voxel size of 80μm at tolerable radiation doses (3μSv) is available for the assessment of trabecular and cortical microarchitecture at the distal radius and tibia. This technique bears excellent precision for both density and microstructure measures. Denosumab's greater potency in suppressing bone remodeling and greater effect on areal BMD than alendronate, particularly at predominantly cortical sites such as the distal third of the radius, may reflect the differing mechanism of action of these drugs, which, in turn, influence bone microarchitecture. The aim of this study is to compare the effects of denosumab and a current standard treatment on cortical and trabecular microarchitecture at the radius and second metacarpal in RA patients with low bone mineral density using HR-pQCT during a 6-month open-label randomized controlled study. One bisphosphonate, namely alendronate sodium (or alendronate) is chosen to generate a heterogeneous and comparable active control group. This is a 6-month open-label randomized controlled clinical trial. Forty ambulatory Chinese females, who consent to receive alendronate as standard treatment subjective to the randomization, will be enrolled from the rheumatology clinic of the Prince of Wales Hospital in this study. Subjects will be randomized to 2 groups receiving: 1) subcutaneous injection of denosumab 60mg (Prolia®) every 6 months (n=20), or 2) a standard treatment: oral alendronate weekly (Fosamax® once weekly 70 mg, n=20). In addition, all patients will be given a daily calcium supplement (1500mg caltrate /day) and 1 multivitamin tablet per day. Efficacy and safety assessment will be performed at baseline, month 3 and month 6. aBMD of lumbar spine, total hip and non-dominant distal radius will be measured using dual-energy X-ray absorptiometry (DXA) and microarchitecture of bone is measured at the non-dominant distal radius and the second metacarpal bone of the non-dominant hand using HR-pQCT.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- with a diagnosis of RA according to the 2010 new 2010 American College of

Rheumatology/ European League Against Rheumatism classification criteria

- at an age over 18 years old

- have a lumbar spine, or total hip or distal radius T-score lower than -1. 5 by DXA

- without severe deformity in metacarpophalangeal (MCP) joints which would influence

the longitudinal assessment of HR-pQCT

- consent to receive alendronate if randomized to standard treatment group.

Exclusion Criteria:

- they have previous use of denosumab, teriparatide, alendronate or other

anti-resorptive agents;

- they have a history of recent major gastrointestinal (GI) tract disease (e. g.

oesophagitis or GI ulceration) or have experienced any previous adverse reaction to bisphosphonate therapy;

- they are receiving other bone-active drugs, such as hormonal replacement therapy,

thyroxine, thiazide and diuretics;

- they have conditions affecting bone metabolism; contraindications to alendronate and

denosumab (uncorrected hypocalcemia);

- they have unexplained hypocalcemia;

- they have severe renal impairment or serum creatinine level of >200umol/L;

- they are pregnant or breastfeeding;

- they do not understand Chinese or are incompetent in giving consent.

Locations and Contacts

Prince of Wales Hospital, Shatin, N.t., Hong Kong
Additional Information

Starting date: December 2012
Last updated: September 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017